<DOC>
	<DOCNO>NCT00308412</DOCNO>
	<brief_summary>Human parainfluenza virus ( HPIVs ) major health concern infant young child 5 year age , cause serious respiratory tract disease . The purpose study test safety immune response new HPIV vaccine healthy infant child .</brief_summary>
	<brief_title>Safety Immune Response Human Parainfluenza Virus Vaccine ( rHPIV3cp45 ) Healthy Infants</brief_title>
	<detailed_description>HPIV type 3 ( HPIV3 ) rank second respiratory syncytial virus important cause bronchiolitis pneumonia infant less 6 month age . HPIV3 cause severe disease first 2 year life responsible 11 % hospitalization respiratory diseases child . This study evaluate safety immunogenicity live recombinant attenuate intranasal HPIV3 vaccine , rHPIV3cp45 . This study last maximum 180 day . Infants enrol one two study group , Group 1 Group 2 . Depending study location , group enroll either sequentially concurrently . Within group , infant randomly assign receive 2 immunization rHPIV3cp45 placebo . Immunizations give nose drop . Immunizations give study entry approximately 4 10 week study entry . On day immunization , physical exam , vital sign measurement , blood collection , medical history occur . Infants observe 15 minute immunization immediate adverse effect . Parents guardian give thermometer take instructed take infant 's temperature . They give study schedule need provide contact phone number study personnel contact phone day immunization . Parents guardian contact telephone day without study visit , Day 1 Day 19 Day 180 immunization , ask illness adverse effect observe immunized infant . Parents guardian need record infant 's temperature daily least 17 day immediately follow immunization . During 17-day period , least 6 study visit associate immunization ; visit occur day immunization approximately 3 , 7 , 10 , 14 , 17 day immunization . At study visit , infant undergo physical exam vital sign measurement . Group 1 participant also undergo nasal wash viral culture . There additional follow-up visit occur sometime 28 70 day first dose 28 35 day second dose ; blood collection occur follow-up visit . Additional visit may require selected day month immunization . Infants experience illness side effect may ask return clinic examination . Parents guardian make aware whether infant receive HPIV vaccine placebo 18 day second immunization event low respiratory tract illness .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Paramyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria All Participants : Good general health Full term infant , bear later 36th week pregnancy Has receive ageappropriate inactivate subunit routine immunization least 2 week prior study entry Has receive ageappropriate live routine immunization least 4 week prior study entry least 2 week rotavirus vaccine Available duration trial Parent guardian reachable telephone postimmunization contact Parent guardian willing provide inform consent For Group 2 participant , serum hemagglutinationinhibiting ( HAI ) titer HPIV3 le 1:8 Known suspect impairment immunologic function . Infants HIV infect , bone marrow solid organ transplant recipient , use immunosuppressive therapy , include systemic corticosteroid , exclude . Infants use topical steroid , topical antibiotic ointment topical antifungal agent exclude . Major congenital malformation , include congenital cleft palate , cytogenetic abnormality , serious chronic disorder Previously receive PIV3 vaccine Previous serious vaccineassociated adverse event anaphylactic reaction Known hypersensitivity vaccine component Lung heart disease , include reactive airway disease . Infants clinically insignificant cardiac abnormality exclude . Infants child wheeze receive bronchodilator therapy first year life additional wheezing episode bronchodilator therapy least 12 month exclude . Born prematurely 37th week pregnancy Member household contain immunocompromised individual , pregnant caregiver , infant le 6 month age Attends day care infant less 6 month age Parent guardian unable unwilling suspend daycare 14 day follow immunization . More information criterion find protocol . Currently enrol another investigational drug vaccine study</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Respiratory Tract Infection</keyword>
</DOC>